ArticleJournal of medical case reports2025
Anti-melanoma differentiation-associated gene 5 antibody associated rapidly progressive interstitial lung disease in a pediatric patient: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease.Case reports in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapidly progressive interstitial lung disease presents as a severe complication of juvenile dermatomyositis, particularly when associated with anti-melanoma differentiation-associated gene 5. We report a pediatric case that underscores the necessity for clinicians to maintain a high index of suspicion for early identification and management. CASE PRESENTATION: A previously healthy 7-year-old White girl presented with a 6-week history of generalized weakness, fever, joint pain, and abdominal pain. Initial examination revealed hypoxia, tachypnea, and hepatosplenomegaly. Laboratory tests were marked by thrombocytopenia, lymphopenia, elevated liver enzymes, high ferritin, high triglyceride, elevated muscle enzymes, and increased soluble IL-2 receptor, suggesting macrophage activation syndrome that was and managed with dexamethasone 5 mg/kg/m
conclusionsThis case demonstrates the diagnostic and therapeutic challenges in patients with rapidly progressive interstitial lung disease in the context of anti-melanoma differentiation-associated gene 5 associated juvenile dermatomyositis, who may not present with overt muscle and cutaneous features of juvenile dermatomyositis and whose lung disease can progress very rapidly. A high index of suspicion among clinicians is critical, and expedited diagnostic serology may assist with earlier diagnosis and initiation of therapy. Extracorporeal membrane oxygenation can be utilized as a bridge to diagnosis in the setting of severe refractory hypoxemic respiratory failure. However, despite aggressive treatment, the prognosis remains challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.